Drug Type Small molecule drug |
Synonyms- |
Target |
Action antagonists |
Mechanism A1R antagonists(Adenosine A1 receptor antagonists), A2aR antagonists(Adenosine A2a receptor antagonists), A2bR antagonists(Adenosine A2b receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC21H22N6O2 |
InChIKeyPMYVFCVHHSNNIQ-MRXNPFEDSA-N |
CAS Registry2570904-69-5 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | South Korea | 22 Oct 2025 | |
| Neoplasms | Preclinical | South Korea | 22 Oct 2025 | |
| Neoplasms | Preclinical | South Korea | 22 Oct 2025 |





